6/23/2021 7:04:18 AM
Clovis Oncology Says Phase 1/2 LuMIERE Study Of FAP-2286 Now Open For Enrollment
6/22/2020 9:03:32 AM
Alkermes : New Preclinical Data On ALKS 4230 In Combination With Lucitanib To Be Presented
3/2/2020 4:07:48 AM
Clovis Oncology Announces Availability For Rubraca Tablets For Women With Relapsed Ovarian Cancer In Spain
2/3/2020 4:02:27 AM
Clovis Oncology Announces Availability For Rubraca Tablets For Women With Relapsed Ovarian Cancer In France
2/27/2018 8:59:50 AM
RBC Capital Markets Is Lowering Clovis Oncology, Inc. (CLVS) FY18 Rev. Estimate To 122.8 M From 131.5 M
2/27/2018 8:59:37 AM
RBC Capital Markets Is Cutting Clovis Oncology, Inc. (CLVS) Q1 18 Rev. Estimate To 18.1 M From 19.6 M
2/27/2018 8:59:19 AM
RBC Capital Markets Is Increasing Clovis Oncology, Inc. (CLVS) FY19 Estimate To -1.64 From -2.02
2/27/2018 8:59:05 AM
RBC Capital Markets Is Raising Clovis Oncology, Inc. (CLVS) FY18 Estimate To -5.34 From -5.65
2/27/2018 8:58:51 AM
RBC Capital Markets Is Increasing Clovis Oncology, Inc. (CLVS) Q1 18 Estimate To -1.39 From -1.46
11/2/2017 12:04:41 PM
RBC Capital Markets Is Cutting Clovis Oncology, Inc. (CLVS) 4Q17 Rev. Estimate To 20.9 M From 26.1 M
11/2/2017 12:04:19 PM
RBC Capital Markets Is Raising Clovis Oncology, Inc. (CLVS) 2019 Estimate To -1.34 From -1.59
11/2/2017 12:03:58 PM
RBC Capital Markets Is Increasing Clovis Oncology, Inc. (CLVS) 2018 Estimate To -3.84 From -4.19
11/2/2017 12:03:35 PM
RBC Capital Markets Is Raising Clovis Oncology, Inc. (CLVS) 2017 Estimate To -7.65 From -7.79
11/2/2017 12:03:20 PM
RBC Capital Markets Is Lowering Clovis Oncology, Inc. (CLVS) 2017 Rev. Estimate To 59.4 M From 68.6 M